Enhancing effect of borneol on pharmacokinetics of ginsenoside Rb1, ginsenoside Rg1, and notoginsenoside R1 in healthy volunteers after oral administration of compound Danshen dropping pills. (14th February 2022)

• Record Type: Journal Article
• Authors: Zheng, Dayong; Chu, Yang; Li, Shuming; Zhou, Shuiping; Li, Wei; Xie, Yuesheng; Sun, He
• Is Part Of: Biomedical chromatography. Volume 36:Number 5(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-02-14
• Subjects: borneol -- LC–MS/MS -- notoginsenosides -- pharmacokinetics; Chromatographic analysis -- Periodicals; Biology -- Periodicals; Medicine -- Periodicals; Biology -- Periodicals; Chromatography -- methods -- Periodicals; Medicine -- Periodicals; 543.089
• DOI: 10.1002/bmc.5311
• Languages: English
• ISSNs: 0269-3879

Abstract

Abstract: Borneol (Bingpian), a monoterpenoid pharmaceutical ingredient, is commonly used as a main composition in traditional Chinese medicine preparations such as compound Danshen dropping pills (CDDP) and has also been approved by the U.S. Food and Drug Administration as a flavoring substance or adjuvant in food. Borneol plays a regulating and guiding role as a messenger drug in CDDP. However, the effect of borneol on the pharmacokinetics of the components of CDDP in human plasma is unclear. In this study, we investigate the effects of borneol on the pharmacokinetics of ginsenoside Rb1 (Rb1 ), ginsenoside Rg1 (Rg1 ), and notoginsenoside R1 (NR1 ) in CDDP. We used a double‐cycle crossover‐administration model in 12 healthy male volunteers, administered CDDP with borneol (drug T) and without borneol (drug R). The selective response monitoring mode was used for MS quantification in the positive mode. As a result, we found that borneol could significantly affect the pharmacokinetic parameters of notoginsenosides and increase the absorption and systemic exposure of Rb1, Rg1, and NR1 in human plasma by ~1.85–3.71 times.